

## NCCN Bladder Cancer V.1.2011 – Update Teleconference – July 8, 2010

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<a href="#">BL-3</a> Panel member request during teleconference to add valrubicin as an intravesical option for subsequent treatment of cTa, cT1, Tis recurrent or persistent disease.	Valrubicin is FDA approved for the indication of BCG-refractory carcinoma in situ of the urinary bladder. The panel added this as an intravesical option for subsequent treatment of cTa, cT1, Tis recurrent or persistent disease.	<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=13342&amp;CFID=1774383&amp;CFTOKEN=50076be3ff7a4b23-5D59A11E-9BF8-C0CD-FEDE9608F82D9DA9&amp;jsessionId=ca301005309622346371">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=13342&amp;CFID=1774383&amp;CFTOKEN=50076be3ff7a4b23-5D59A11E-9BF8-C0CD-FEDE9608F82D9DA9&amp;jsessionId=ca301005309622346371</a>	9	0	0